35162-44-8

Usage

Uses

Used in Pharmaceutical Research and Development:
(2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE is used as a research compound for its potential medicinal properties, particularly in the development of antiviral or antibacterial agents. Its unique structure and the presence of the hydroxyimino group make it a promising candidate for further investigation and application in the pharmaceutical industry.
Used in Scientific Research:
In the laboratory setting, (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE serves as a valuable tool for scientific research. Researchers can use (2E)-N-(3,5-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE to study its chemical properties, interactions with biological systems, and potential therapeutic effects. Its use in scientific research aids in the advancement of knowledge in the fields of chemistry and medicine.

InChI:InChI=1/C10H12N2O2/c1-7-3-8(2)5-9(4-7)12-10(13)6-11-14/h3-6,14H,1-2H3,(H,12,13)/b11-6-

Upstream product

• 302-17-0 chloral hydrate 
• 108-69-0 3,5-dimethylaminoaniline 

Downstream Products

• 90321-33-8 2-amino-4,6-dimethyl-benzoic acid 
• 875241-52-4 2-amino-4,6-dimethyl benzamide 
• 1246250-87-2 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Further Studies on Triazinoindoles as Potential Novel Multitarget-Directed Anti-Alzheimer's Agents

The inadequate clinical efficacy of the present anti-Alzheimer's disease (AD) drugs and their low impact on the progression of Alzheimer's disease in patients have revised the research focus from single targets to multitarget-directed ligands. A novel series of substituted triazinoindole derivatives were obtained by introducing various substituents on the indole ring for the development of multitarget-directed ligands as anti-AD agents. The experimental data indicated that some of these compounds exhibited significant anti-AD properties. Among them, 8-(piperidin-1-yl)-N-(6-(pyrrolidin-1-yl)hexyl)-5H-[1,2,4]triazino[5,6-b]indol-3-amine (60), the most potent cholinesterase inhibitor (AChE, IC50 value of 0.32 μM; BuChE, IC50 value of 0.21 μM), was also found to possess significant self-mediated Aβ1-42 aggregation inhibitory activity (54% at 25 μM concentration). Additionally, compound 60 showed strong antioxidant activity. In the PAMPA assay, compound 60 exhibited blood-brain barrier penetrating ability. An acute toxicity study in rats demonstrated no sign of toxicity at doses up to 2000 mg/kg. Furthermore, compound 60 significantly restored the cognitive deficits in the scopolamine-induced mice model and Aβ1-42-induced rat model. In the in silico ADMET prediction studies, the compound satisfied all the parameters of CNS acting drugs. These results highlighted the potential of compound 60 to be a promising multitarget-directed ligand for the development of potential anti-AD drugs.

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.